Mito-LND
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS) . Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells[1].
Product Specifications
CAS Number
2361564-49-8
Product Name Alternative
Mito-Lonidamine
UNSPSC
12352005
Target
Autophagy; Mitochondrial Metabolism; Oxidative Phosphorylation; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mito-lnd.html
Purity
97.00
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(NCCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C4=NN(CC5=CC=C(Cl)C=C5Cl)C6=C4C=CC=C6.[Br-]
Molecular Formula
C43H45BrCl2N3OP
Molecular Weight
801.62
References & Citations
[1]Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10 (1) :2205.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
AKT1 (Prognostic Marker for Neuroendocrine Tumors) (AKT1/2491), CF594 conjugate, 0.1mg/mL
